Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24‐week randomized placebo‐controlled trial
The DOI matches its Crossref record.
Abstract
Aim: Assess safety/tolerability and efficacy of the DPP‐4 inhibitor vildagliptin in 515 patients with type 2 diabetes mellitus (T2DM) and moderate or severe renal impairment (RI). Methods: Double‐blind, randomized, parallel‐group, placebo‐controlled, 24‐week clinical trial assessing safety and efficacy of vildagliptin (50 mg qd) added to current antidiabetic therapy, in patients with T2DM and moderate or severe RI (GFR ≥ 30 to <50 or <30 ml/min/1.73 m 2 ). Results: The study population comprised of 165 and 129 patients with moderate RI and 124 and 97 patients with severe RI randomized to vildagliptin and placebo, respectively, with most patients receiving background insulin therapy (68 and 81% for moderate and severe RI, respectively). After 24 weeks, the between‐treatment difference in the adjusted mean change in A1C was −0.5 ± 0.1% (p < 0.0001) in moderate RI (baseline A1C = 7.9%) and −0.6 ± 0.1% (p < 0.0001) in severe RI (baseline A1C = 7.7%). In patients with moderate RI, similar proportions of those receiving vildagliptin or placebo experienced any AE (68 vs. 73%), any SAE (9 vs. 9%), any AE leading to discontinuation (3 vs. 5%) or death (1 vs. 1%). This was also true for patients with severe RI: AEs (73 vs. 74%), SAEs (19 vs. 21%), AEs leading to discontinuation (9 vs. 6%) and death (2 vs. 4%). Conclusions: In this 24‐week study of 515 patients with T2DM and moderate or severe RI, vildagliptin added to ongoing antidiabetic therapy had a safety profile similar to placebo. Further, relative to placebo, vildagliptin elicited a statistically and clinically significant decrease in A1C in patients with moderate or severe RI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 20
- 10.5694/j.1326-5377.2006.tb00499.x · DOI · Paper page
- 10.1053/j.ajkd.2007.08.012 · DOI
- 10.1592/phco.30.5.463 · DOI · Paper page
- 10.1111/j.1463-1326.2010.01215.x · DOI · Paper page
- 10.2147/VHRM.S16925 · DOI
- 10.1111/j.1463-1326.2010.01214.x · DOI · Paper page
- 10.1186/1472-6823-8-14 · DOI · Paper page
- 10.1111/j.1463-1326.2011.01382.x · DOI · Paper page
- 10.1111/j.1463-1326.2008.00914.x · DOI · Paper page
- 10.1124/dmd.108.023010 · DOI
- 10.1016/j.diabres.2006.12.009 · DOI · Paper page
- 10.1055/s-2007-970422 · DOI · Paper page
- 10.1111/j.1463-1326.2010.01325.x · DOI · Paper page
- 10.1016/j.diabres.2010.06.022 · DOI
- 10.1111/j.1463-1326.2011.01414.x · DOI · Paper page
- 10.1007/s00125-007-0633-0 · DOI · Paper page
- 10.1111/j.1463-1326.2008.00859.x · DOI · Paper page
- 10.2337/dc07-1188 · DOI
- 10.1007/s11892-009-0076-8 · DOI
- 10.1210/jc.2008-2152 · DOI · Paper page
Cited by
Palmer, S. C., Tendal, B., Mustafa, R. A., Vandvik, P. O., Li, S., Hao, Q., Tunnicliffe, D., Ruospo, M., Natale, P., Saglimbene, V., et al. (2021) · BMJ · doi:10.1136/bmj.m4573 · Cited by 679
Update on the treatment of type 2 diabetes mellitus
Marín-Peñalver, J. J., Martín-Timón, I., Sevillano-Collantes, C., & Cañizo-Gómez, F. J. D. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i17.354 · Cited by 647
Haidinger, M., Werzowa, J., Hecking, M., Antlanger, M., Stemer, G., Pleiner, J., Kopecky, C., Kovarik, J. J., Döller, D., Pacini, G., et al. (2014) · American Journal of Transplantation · doi:10.1111/ajt.12518 · Cited by 110
Cooper, M. E., Perkovic, V., McGill, J. B., Groop, P.-H., Wanner, C., Rosenstock, J., Hehnke, U., Woerle, H.-J., & von Eynatten, M. (2015) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2015.03.024 · Cited by 110
Self-citationScheen, A. J. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0198-2 · Cited by 102
“HbA1c reductions seen in T2DM patients with CKD treated with 50 mg once daily were similar to the reductions observed with the vildagliptin 50 mg twice-daily dose in a similar population with preserved renal function and a similar baseline HbA1c [55].”
BackgroundMethod
Metadata
- Authors
- Lukashevich, V., Schweizer, A., Shao, Q., Groop, P. ‐., & Kothny, W.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2011-09-06
- Volume
- 13
- Issue
- 10
- Pages
- 947-954
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2079841945
- Cited by
- 146
- References
- 0
- FWCI
- 18.36
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24‐week randomized placebo‐controlled trial. https://app.cochat.ai/papers/10.1111/j.1463-1326.2011.01467.x
- The paper
- Lukashevich, V., Schweizer, A., Shao, Q., Groop, P. ‐., & Kothny, W. (2011). Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24‐week randomized placebo‐controlled trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2011.01467.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.